Global Cancer Monoclonal Antibodies Market &Clinical Trial Insight 2024
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
'Global Cancer Monoclonal Antibodies Market &Clinical Trial Insight 2024' Report Highlights:
Though the monoclonal antibodies are already a significant part of the treatment for many cancers, the use of these antibodies in other aspects of cancer treatment is yet to be tapped. In this regard, research is currently being undertaken to understand deeply the process and reason for cancer cells being different from normal cells and the use of mAbs to exploit these differences. This has led to the development of many newer forms of mAbs, which are being attached to drugs or other substances thus making them more powerful.
The pharma companies are also looking for ways and means to make these drugs more safe and effective. As an illustration, since mAbs are proteins, there is a high chance that these antibodies could possibly make the body’s immune system react against them, which could result in many side effects, and also destruction of the mAbs. The newly developed forms of mAbs are a solution to this problem and are less likely to cause immune reactions.
Pharma companies are also working on the options for using only some specific parts of antibodies to develop improvised drugs. Another approach which is also currently being analyzed is to combine parts of two antibodies together (known as a bispecific antibody). In this process, one part could possibly attach to a cancer cell, while the other could attach to an immune cell, which would eventually bring both together. Thus, the future years are likely to witness an increased use of mAbs in different forms in treating cancer so as to provide better treatment options and thus improve the patient’s lives. The pharma companies have realized the potential of mAbs in this field and are focusing their efforts in developing these antibodies at the earliest to capture a significant market share.
It is expected that during the next decade, with the discovery and introduction of new tumor-specific proteins, newer MAb targets would be successfully identified for regulating tumor cell growth or inducing apoptosis. Additionally, the changes in MAb would also allow for more efficient radionuclide or cytotoxic MAb drug targeting or lead to more efficient activation of host effector mechanisms which tend to lead to better therapeutic antibodies.
'Global Cancer Monoclonal Antibodies Market &Clinical Trial Insight 2024' Report Highlights:
- Significance for Monoclonal Antibodies for Cancer Treatment
- Global Cancer Monoclonal Antibodies Market Overview
- Global Cancer Monoclonal Antibodies Pipeline by Phase & Indication
- Global Cancer Monoclonal Antibodies Pipeline: 697 mAb
- Marketed Cancer Monoclonal Antibodies: 60
- Global Cancer Monoclonal Antibodies Market Opportunity: US$ 140 Billion
Though the monoclonal antibodies are already a significant part of the treatment for many cancers, the use of these antibodies in other aspects of cancer treatment is yet to be tapped. In this regard, research is currently being undertaken to understand deeply the process and reason for cancer cells being different from normal cells and the use of mAbs to exploit these differences. This has led to the development of many newer forms of mAbs, which are being attached to drugs or other substances thus making them more powerful.
The pharma companies are also looking for ways and means to make these drugs more safe and effective. As an illustration, since mAbs are proteins, there is a high chance that these antibodies could possibly make the body’s immune system react against them, which could result in many side effects, and also destruction of the mAbs. The newly developed forms of mAbs are a solution to this problem and are less likely to cause immune reactions.
Pharma companies are also working on the options for using only some specific parts of antibodies to develop improvised drugs. Another approach which is also currently being analyzed is to combine parts of two antibodies together (known as a bispecific antibody). In this process, one part could possibly attach to a cancer cell, while the other could attach to an immune cell, which would eventually bring both together. Thus, the future years are likely to witness an increased use of mAbs in different forms in treating cancer so as to provide better treatment options and thus improve the patient’s lives. The pharma companies have realized the potential of mAbs in this field and are focusing their efforts in developing these antibodies at the earliest to capture a significant market share.
It is expected that during the next decade, with the discovery and introduction of new tumor-specific proteins, newer MAb targets would be successfully identified for regulating tumor cell growth or inducing apoptosis. Additionally, the changes in MAb would also allow for more efficient radionuclide or cytotoxic MAb drug targeting or lead to more efficient activation of host effector mechanisms which tend to lead to better therapeutic antibodies.
1. INTRODUCTION TO MONOCLONAL ANTIBODIES
1.1 History of Development
1.2 Working of Monoclonal Antibodies
2. MONOCLONAL ANTIBODIES CLASSIFICATION
2.1 Naked Monoclonal Antibodies
2.2 Conjugated Monoclonal Antibodies
2.2.1 Radiolabeled Antibodies
2.2.2 Chemolabeled Antibodies
2.2.3 Immunotoxins
3. MONOCLONAL ANTIBODIES MECHANISMS
3.1 Tumor Antigens as Targets of Antibodies
3.2 Development of Antibodies for Clinical Purposes
3.3 Complement Dependent Cytotoxicity (CDC)
3.4 Signal Transduction Changes
4. SIGNIFICANCE FOR MONOCLONAL ANTIBODIES FOR CANCER TREATMENT
5. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET OVERVIEW
5.1 Current Market Scenario
5.2 Clinical Pipeline Insight
6. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET FUTURE OUTLOOK
7. GLOBAL - BLADDER CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE
7.1 Phase-I/II
7.2 Phase-II
7.3 Phase-III
8. MARKETED BLADDER CANCER MONOCLONAL ANTIBODIES CLINICAL INSIGHT
8.1 Durvalumab (Imfinzi)
9. GLOBAL - BLOOD CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE
9.1 Unknown
9.2 Research
9.3 Preclinical
9.4 Clinical
9.5 Phase-I
9.6 Phase-I/II
9.7 Phase-II
9.8 Phase-III
9.9 Preregistration
10. MARKETED BLOOD CANCER MONOCLONAL ANTIBODIES CLINICAL INSIGHT
10.1 Daratumumab (DARZALEX)
10.2 Ofatumumab (Arzerra)
10.3 Obinutuzumab (GAZYVA, Gazyva & Gazyvaro)
10.4 Blinatumomab (Blincyto)
10.5 Elotuzumab (Empliciti)
10.6 Mogamulizumab (Poteligeo)
10.7 Alemtuzumab (Campath, Lemtrada, MabCampath, MabKampat & Remniq)
10.8 Brentuximab Vedotin (Adcetris)
10.9 Inotuzumab Ozogamicin (BESPONSA & Besponsa)
10.10 Rituximab Biosimilar (AcellBia, Acellbia & USMAL)
10.11 Rituximab Biosimilar (Blitzima, Ritemvia, Truxima & Tuxella)
10.12 Rituximab Biosimilar (Rixathon & Riximyo)
10.13 Gemtuzumab Ozogamicin (Mylotarg)
10.14 Ibritumomab Tiuxetan (Zevalin & Zevamab)
10.15 Rituximab Biosimilar (REDDITUX, Reditux & Tidecron)
10.16 Rituximab Biosimilar (Novex)
10.17 Rituximab Biosimilar (CIMAbior & RituxCIM)
10.18 Rituximab/Hyaluronidase (MabThera SC, RITUXAN SC & Rituxan Hycela)
10.19 Rituximab Biosimilar (Zytux)
10.20 Rituximab Biosimilar (RituxiRel, Toritz & Toritz RA)
10.21 Rituximab Biosimilar (Maball)
10.22 Rituximab Biosimilar (Kikuzubam)
10.23 Rituximab Biosimilar (Mabtas)
11. GLOBAL - BREAST CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE
11.1 Unknown
11.2 Research
11.3 Preclinical
11.4 Phase-I
11.5 Phase-II
11.6 Phase-III
11.7 Preregistration
11.8 Registered
12. MARKETED BREAST CANCER MONOCLONAL ANTIBODIES CLINICAL INSIGHT
12.1 Trastuzumab Subcutaneous (Herceptin SC)
12.2 Pertuzumab (Omnitarg & Perjeta)
12.3 Trastuzumab Biosimilar (CANMAb, Hertraz, Ogivri & Zedora)
12.4 Trastuzumab Emtansine (Kadcyla)
12.5 Trastuzumab Biosimilar (Vivitra)
13. GLOBAL BONE CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE
13.1 Phase-III
14. MARKETED BONE CANCER MONOCLONAL ANTIBODIES CLINICAL INSIGHT
14.1 Denosumab (PRALIA, Prolia, Ranmark & Xgeva)
15. GLOBAL - BRAIN CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE
15.1 Preclinical
15.2 Phase-I/II
15.3 Phase-III
15.4 Registered
16. MARKETED BRAIN CANCER MONOCLONAL ANTIBODIES CLINICAL INSIGHT
16.1 Dinutuximab (Unituxin)
17. GLOBAL - CERVICAL CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE
17.1 Phase-I/II
18. GLOBAL - COLORECTAL CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE
18.1 Unknown
18.2 Preclinical
18.3 Phase-I
19. GLOBAL - HEAD AND NECK CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE
19.1 Preclinical
19.2 Phase-I/II
19.3 Phase-III
20. GLOBAL - LIVER CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE
20.1 Phase-II
21. GLOBAL - KIDNEY CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE
21.1 Preclinical
21.2 Phase-II
21.3 Phase-III
22. GLOBAL - SKIN CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE
22.1 Research
22.2 Preclinical
22.3 Phase-I
22.4 Phase-I/II
22.5 Phase-II/III
22.6 Phase-III
22.7 Preregistration
23. MARKETED SKIN CANCER MONOCLONAL ANTIBODIES CLINICAL INSIGHT
23.1 Avelumab (BAVENCIO)
23.2 Olaratumab (Lartruvo)
24. GLOBAL - STOMACH CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE
24.1 Preclinical
24.2 Phase-I/II
24.3 Phase-II
24.4 Phase-III
24.5 Preregistration
25. MARKETED STOMACH CANCER MONOCLONAL ANTIBODIES CLINICAL
25.1 Bevacizumab Biosimilar (Bevax)
25.2 Cetuximab Biosimilar – CinnaGen
25.3 Bevacizumab Biosimilar (Cizumab)
26. GLOBAL - LUNG CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE
26.1 Research
26.2 Clinical
26.3 Phase-I
26.4 Phase-I/II
26.5 Phase-II
26.6 Phase-II/III
26.7 Phase-III
26.8 Preregistration
26.9 Registered
27. MARKETED LUNG CANCER MONOCLONAL ANTIBODIES CLINICAL INSIGHT
27.1 Necitumumab (Portrazza)
27.2 Iodine I 131 Derlotuximab Biotin (Cotara)
27.3 Bevacizumab Biosimilar (Bryxta)
27.4 Racotumomab (Vaxira)
27.5 Racotumomab (Vaxira)
27.6 Tc 99m Nofetumomab Merpentan (VerLuma)
28. GLOBAL - OVARIAN CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE
28.1 Research
28.2 Preclinical
28.3 Phase-I
28.4 Phase-I/II
28.5 Phase-II
29. GLOBAL - PANCREATIC CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE
29.1 Preclinical
29.2 Phase-I
29.3 Phase-I/II
29.4 Phase-II
30. MARKETED PANCREATIC CANCER MONOCLONAL ANTIBODIES CLINICAL INSIGHT
30.1 Gemcitabine elaidate companion diagnostic - Ventana Medical Systems/Clovis Oncology
31. GLOBAL - PROSTATE CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE
31.1 Preclinical
31.2 Phase-II
32. GLOBAL - MULTIPLE CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE
32.1 Unknown
32.2 Research
32.3 Preclinical
32.4 Clinical
32.5 Phase-I
32.6 Phase-I/II
32.7 Phase-II
32.8 Phase-II/III
32.9 Phase-III
32.10 Registered
33. MARKETED MULTIPLE CANCER MONOCLONAL ANTIBODIES CLINICAL INSIGHT
33.1 Cetuximab (Erbitux)
33.2 Nivolumab (Opdivo)
33.3 Bevacizumab (Avastin)
33.4 Trastuzumab (Herceptin)
33.5 Atezolizumab (TECENTRIQ)
33.6 Rituximab (MabThera & Rituxan)
33.7 Ramucirumab (Cyramza, Sairamza & Silamza)
33.8 Trastuzumab Biosimilar (Herzuma)
33.9 Pembrolizumab (Keytruda)
33.10 Pembrolizumab Companion Diagnostic (PD-L1 IHC 22C3 pharmDx)
33.11 Ipilimumab (Yervoy)
33.12 Trastuzumab Biosimilar (BIOMAb EGFR, CIMAher, Cimaher, Taixinsheng, TheraCIM, Theraloc & VECTHIX)
33.13 Nimotuzumab (BIOMAb EGFR, CIMAher, Cimaher, Taixinsheng, TheraCIM, Theraloc & VECTHIX)
33.14 Bevacizumab Biosimilar (KRABEVA)
33.15 Bevacizumab Biosimilar (Mvasi)
33.16 Trastuzumab Biosimilar (AryoTrust)
33.17 Satumomab (OncoScint CR/OV)
34. COMPETITIVE LANDSCAPE
34.1 Abbvie
34.2 Amgen
34.3 Bayer HealthCare
34.4 Biogen Idec
34.5 Eli Lilly
34.6 Genmab
34.7 Gilead Sciences
34.8 GlaxoSmithKline
34.9 Novartis
34.10 Pfizer
34.11 Roche
34.12 Seattle Genetics
1.1 History of Development
1.2 Working of Monoclonal Antibodies
2. MONOCLONAL ANTIBODIES CLASSIFICATION
2.1 Naked Monoclonal Antibodies
2.2 Conjugated Monoclonal Antibodies
2.2.1 Radiolabeled Antibodies
2.2.2 Chemolabeled Antibodies
2.2.3 Immunotoxins
3. MONOCLONAL ANTIBODIES MECHANISMS
3.1 Tumor Antigens as Targets of Antibodies
3.2 Development of Antibodies for Clinical Purposes
3.3 Complement Dependent Cytotoxicity (CDC)
3.4 Signal Transduction Changes
4. SIGNIFICANCE FOR MONOCLONAL ANTIBODIES FOR CANCER TREATMENT
5. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET OVERVIEW
5.1 Current Market Scenario
5.2 Clinical Pipeline Insight
6. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET FUTURE OUTLOOK
7. GLOBAL - BLADDER CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE
7.1 Phase-I/II
7.2 Phase-II
7.3 Phase-III
8. MARKETED BLADDER CANCER MONOCLONAL ANTIBODIES CLINICAL INSIGHT
8.1 Durvalumab (Imfinzi)
9. GLOBAL - BLOOD CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE
9.1 Unknown
9.2 Research
9.3 Preclinical
9.4 Clinical
9.5 Phase-I
9.6 Phase-I/II
9.7 Phase-II
9.8 Phase-III
9.9 Preregistration
10. MARKETED BLOOD CANCER MONOCLONAL ANTIBODIES CLINICAL INSIGHT
10.1 Daratumumab (DARZALEX)
10.2 Ofatumumab (Arzerra)
10.3 Obinutuzumab (GAZYVA, Gazyva & Gazyvaro)
10.4 Blinatumomab (Blincyto)
10.5 Elotuzumab (Empliciti)
10.6 Mogamulizumab (Poteligeo)
10.7 Alemtuzumab (Campath, Lemtrada, MabCampath, MabKampat & Remniq)
10.8 Brentuximab Vedotin (Adcetris)
10.9 Inotuzumab Ozogamicin (BESPONSA & Besponsa)
10.10 Rituximab Biosimilar (AcellBia, Acellbia & USMAL)
10.11 Rituximab Biosimilar (Blitzima, Ritemvia, Truxima & Tuxella)
10.12 Rituximab Biosimilar (Rixathon & Riximyo)
10.13 Gemtuzumab Ozogamicin (Mylotarg)
10.14 Ibritumomab Tiuxetan (Zevalin & Zevamab)
10.15 Rituximab Biosimilar (REDDITUX, Reditux & Tidecron)
10.16 Rituximab Biosimilar (Novex)
10.17 Rituximab Biosimilar (CIMAbior & RituxCIM)
10.18 Rituximab/Hyaluronidase (MabThera SC, RITUXAN SC & Rituxan Hycela)
10.19 Rituximab Biosimilar (Zytux)
10.20 Rituximab Biosimilar (RituxiRel, Toritz & Toritz RA)
10.21 Rituximab Biosimilar (Maball)
10.22 Rituximab Biosimilar (Kikuzubam)
10.23 Rituximab Biosimilar (Mabtas)
11. GLOBAL - BREAST CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE
11.1 Unknown
11.2 Research
11.3 Preclinical
11.4 Phase-I
11.5 Phase-II
11.6 Phase-III
11.7 Preregistration
11.8 Registered
12. MARKETED BREAST CANCER MONOCLONAL ANTIBODIES CLINICAL INSIGHT
12.1 Trastuzumab Subcutaneous (Herceptin SC)
12.2 Pertuzumab (Omnitarg & Perjeta)
12.3 Trastuzumab Biosimilar (CANMAb, Hertraz, Ogivri & Zedora)
12.4 Trastuzumab Emtansine (Kadcyla)
12.5 Trastuzumab Biosimilar (Vivitra)
13. GLOBAL BONE CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE
13.1 Phase-III
14. MARKETED BONE CANCER MONOCLONAL ANTIBODIES CLINICAL INSIGHT
14.1 Denosumab (PRALIA, Prolia, Ranmark & Xgeva)
15. GLOBAL - BRAIN CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE
15.1 Preclinical
15.2 Phase-I/II
15.3 Phase-III
15.4 Registered
16. MARKETED BRAIN CANCER MONOCLONAL ANTIBODIES CLINICAL INSIGHT
16.1 Dinutuximab (Unituxin)
17. GLOBAL - CERVICAL CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE
17.1 Phase-I/II
18. GLOBAL - COLORECTAL CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE
18.1 Unknown
18.2 Preclinical
18.3 Phase-I
19. GLOBAL - HEAD AND NECK CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE
19.1 Preclinical
19.2 Phase-I/II
19.3 Phase-III
20. GLOBAL - LIVER CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE
20.1 Phase-II
21. GLOBAL - KIDNEY CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE
21.1 Preclinical
21.2 Phase-II
21.3 Phase-III
22. GLOBAL - SKIN CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE
22.1 Research
22.2 Preclinical
22.3 Phase-I
22.4 Phase-I/II
22.5 Phase-II/III
22.6 Phase-III
22.7 Preregistration
23. MARKETED SKIN CANCER MONOCLONAL ANTIBODIES CLINICAL INSIGHT
23.1 Avelumab (BAVENCIO)
23.2 Olaratumab (Lartruvo)
24. GLOBAL - STOMACH CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE
24.1 Preclinical
24.2 Phase-I/II
24.3 Phase-II
24.4 Phase-III
24.5 Preregistration
25. MARKETED STOMACH CANCER MONOCLONAL ANTIBODIES CLINICAL
25.1 Bevacizumab Biosimilar (Bevax)
25.2 Cetuximab Biosimilar – CinnaGen
25.3 Bevacizumab Biosimilar (Cizumab)
26. GLOBAL - LUNG CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE
26.1 Research
26.2 Clinical
26.3 Phase-I
26.4 Phase-I/II
26.5 Phase-II
26.6 Phase-II/III
26.7 Phase-III
26.8 Preregistration
26.9 Registered
27. MARKETED LUNG CANCER MONOCLONAL ANTIBODIES CLINICAL INSIGHT
27.1 Necitumumab (Portrazza)
27.2 Iodine I 131 Derlotuximab Biotin (Cotara)
27.3 Bevacizumab Biosimilar (Bryxta)
27.4 Racotumomab (Vaxira)
27.5 Racotumomab (Vaxira)
27.6 Tc 99m Nofetumomab Merpentan (VerLuma)
28. GLOBAL - OVARIAN CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE
28.1 Research
28.2 Preclinical
28.3 Phase-I
28.4 Phase-I/II
28.5 Phase-II
29. GLOBAL - PANCREATIC CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE
29.1 Preclinical
29.2 Phase-I
29.3 Phase-I/II
29.4 Phase-II
30. MARKETED PANCREATIC CANCER MONOCLONAL ANTIBODIES CLINICAL INSIGHT
30.1 Gemcitabine elaidate companion diagnostic - Ventana Medical Systems/Clovis Oncology
31. GLOBAL - PROSTATE CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE
31.1 Preclinical
31.2 Phase-II
32. GLOBAL - MULTIPLE CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE
32.1 Unknown
32.2 Research
32.3 Preclinical
32.4 Clinical
32.5 Phase-I
32.6 Phase-I/II
32.7 Phase-II
32.8 Phase-II/III
32.9 Phase-III
32.10 Registered
33. MARKETED MULTIPLE CANCER MONOCLONAL ANTIBODIES CLINICAL INSIGHT
33.1 Cetuximab (Erbitux)
33.2 Nivolumab (Opdivo)
33.3 Bevacizumab (Avastin)
33.4 Trastuzumab (Herceptin)
33.5 Atezolizumab (TECENTRIQ)
33.6 Rituximab (MabThera & Rituxan)
33.7 Ramucirumab (Cyramza, Sairamza & Silamza)
33.8 Trastuzumab Biosimilar (Herzuma)
33.9 Pembrolizumab (Keytruda)
33.10 Pembrolizumab Companion Diagnostic (PD-L1 IHC 22C3 pharmDx)
33.11 Ipilimumab (Yervoy)
33.12 Trastuzumab Biosimilar (BIOMAb EGFR, CIMAher, Cimaher, Taixinsheng, TheraCIM, Theraloc & VECTHIX)
33.13 Nimotuzumab (BIOMAb EGFR, CIMAher, Cimaher, Taixinsheng, TheraCIM, Theraloc & VECTHIX)
33.14 Bevacizumab Biosimilar (KRABEVA)
33.15 Bevacizumab Biosimilar (Mvasi)
33.16 Trastuzumab Biosimilar (AryoTrust)
33.17 Satumomab (OncoScint CR/OV)
34. COMPETITIVE LANDSCAPE
34.1 Abbvie
34.2 Amgen
34.3 Bayer HealthCare
34.4 Biogen Idec
34.5 Eli Lilly
34.6 Genmab
34.7 Gilead Sciences
34.8 GlaxoSmithKline
34.9 Novartis
34.10 Pfizer
34.11 Roche
34.12 Seattle Genetics
LIST OF FIGURES
Figure 1-1: History of Development of Monoclonal Antibodies
Figure 1-2: Working of Monoclonal Antibodies
Figure 2-1: Types of Monoclonal Antibodies
Figure 5-1: Global Biologics Market Classification
Figure 5-2: Global Market for Monoclonal Antibodies (US$ Billion), 2018-2024
Figure 5-3: Global - Bladder Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-4: Global - Bladder Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-5: Global – Blood Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-6: Global – Blood Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-7: Global – Breast Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-8: Global – Breast Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-9: Global – Bone Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-10: Global – Bone Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-11: Global – Brain Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-12: Global – Brain Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-13: Global – Colorectal Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-14: Global – Colorectal Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-15: Global – Head and Neck Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-16: Global – Head and Neck Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-17: Global – Kidney Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-18: Global – Kidney Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-19: Global – Skin Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-20: Global – Skin Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-21: Global – Stomach Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-22: Global – Stomach Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-23: Global – Lung Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-24: Global – Lung Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-25: Global – Ovarian Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-26: Global – Ovarian Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-27: Global – Pancreatic Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-28: Global – Pancreatic Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-29: Global – Prostate Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-30: Global – Prostate Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-31: Global – Multiple Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-32: Global – Multiple Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-33: Global – Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-34: Global – Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 1-1: History of Development of Monoclonal Antibodies
Figure 1-2: Working of Monoclonal Antibodies
Figure 2-1: Types of Monoclonal Antibodies
Figure 5-1: Global Biologics Market Classification
Figure 5-2: Global Market for Monoclonal Antibodies (US$ Billion), 2018-2024
Figure 5-3: Global - Bladder Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-4: Global - Bladder Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-5: Global – Blood Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-6: Global – Blood Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-7: Global – Breast Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-8: Global – Breast Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-9: Global – Bone Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-10: Global – Bone Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-11: Global – Brain Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-12: Global – Brain Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-13: Global – Colorectal Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-14: Global – Colorectal Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-15: Global – Head and Neck Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-16: Global – Head and Neck Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-17: Global – Kidney Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-18: Global – Kidney Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-19: Global – Skin Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-20: Global – Skin Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-21: Global – Stomach Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-22: Global – Stomach Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-23: Global – Lung Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-24: Global – Lung Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-25: Global – Ovarian Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-26: Global – Ovarian Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-27: Global – Pancreatic Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-28: Global – Pancreatic Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-29: Global – Prostate Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-30: Global – Prostate Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-31: Global – Multiple Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 5-32: Global – Multiple Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-33: Global – Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
Figure 5-34: Global – Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
